(Q33699364)

28 July 2017

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort (English)

1 reference

Francesca Ceccherini-Silberstein

28 July 2017

1 reference

3

Francesca Ceccherini-Silberstein

1 reference

28 July 2017

Alessandro Cozzi-Lepri

2

Antonella d'Arminio Monforte

Alessandro Cozzi-Lepri

0 references

1

Antonella d'Arminio Monforte

0 references

Enrico Girardi

Enrico Girardi

12

0 references

Antonella Castagna

Antonella Castagna

6

0 references

Andrea De Luca

Andrea De Luca

4

0 references

Andrea Antinori

14

Andrea Antinori

1 reference

28 July 2017

11

Andrea Gori

1 reference

28 July 2017

7

Cristina Mussini

1 reference

28 July 2017

15

Massimo Puoti

1 reference

28 July 2017

8

Antonella Cingolani

1 reference

28 July 2017

9

Alessandro Tavelli

1 reference

28 July 2017

10

Milensu Shanyinde

1 reference

28 July 2017

13

Massimo Andreoni

1 reference

28 July 2017

Sergio Lo Caputo

5

1 reference

28 July 2017

Icona Foundation and HepaIcona Study Group

16

1 reference

28 July 2017

language of work or name

English

0 references

publication date

17 May 2017

1 reference

28 July 2017

1 reference

28 July 2017

12

1 reference

28 July 2017

5

1 reference

28 July 2017

e0177402

1 reference

Creative Commons Attribution 4.0 International

28 July 2017

start time

17 May 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Sofosbuvir for previously untreated chronic hepatitis C infection

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5435319

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

28 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0177402

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0177402

Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0177402

Hepatitis C: the path towards effective universal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0177402

Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0177402

EASL Recommendations on Treatment of Hepatitis C 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0177402

10.1371/JOURNAL.PONE.0177402

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

0 references

1 reference

28 July 2017

1 reference